DT-061 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as an allosteric activator of protein phosphatase 2A (PP2A), a tumor suppressor protein that is often inactivated in various cancers. By restoring PP2A activity, DT-061 helps to inhibit cancer cell proliferation and induce apoptosis, making it a promising candidate for targeted cancer therapies. Research is ongoing to explore its efficacy in combination with other anticancer agents and its potential to overcome drug resistance in certain cancers. Additionally, DT-061 is being studied for its role in modulating cellular signaling pathways, which could have broader implications in treating other diseases characterized by dysregulated signaling.